Core Insights - Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first- or best-in-class therapies for autoimmune diseases and cancer [3] Group 1: Company Overview - Cullinan Therapeutics is advancing high-impact therapies leveraging expertise in T cell engagers, which are currently established in oncology and expanding into autoimmune diseases [3] - The company has a clinical-stage pipeline built on a rigorous scientific approach and innovation aimed at delivering new standards of care for patients [3] Group 2: Upcoming Events - The CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 11:00 a.m. ET [1] - A webcast of the fireside chat will be available on the company's investor relations website [2]

Core Insights - Ocular Therapeutix is preparing to present topline results from the SOL-1 Phase 3 superiority trial for AXPAXLI™ in wet AMD at the 49 Macula Society Annual Meeting scheduled for February 25-28, 2026 [1][3] - The company plans to submit a New Drug Application (NDA) for AXPAXLI based on the SOL-1 52-week data, contingent on positive results and discussions with the FDA [1][3] - The SOL-R Phase 3 non-inferiority trial has completed randomization of 631 subjects, with topline results expected in Q1 2027 [1][3] - Ocular has a cash balance of $737.1 million as of December 31, 2025, which is projected to support operations into 2028 [1][5] Business Highlights - The SOL-1 trial is designed to evaluate the safety and efficacy of AXPAXLI in treating wet AMD, with a primary endpoint focused on maintaining visual acuity [3][16] - The SOL-R trial aims to demonstrate non-inferiority compared to aflibercept, with a primary endpoint at Week 56 [3][19] - The HELIOS-3 trial for diabetic retinopathy is currently underway, with a focus on subjects with moderately severe to severe non-proliferative diabetic retinopathy [4][24] Financial Performance - Total net revenue for Q4 2025 was $13.3 million, a decrease of 22.4% from $17.1 million in Q4 2024 [6] - For the full year 2025, total net revenue was $52.0 million, down 18.5% from $63.7 million in 2024 [6] - Research and development expenses increased to $50.8 million in Q4 2025 from $41.0 million in Q4 2024, reflecting ongoing clinical trial costs [7] - The company reported a net loss of $(64.7) million for Q4 2025, consistent with a net loss of $(48.4) million in Q4 2024 [10] Future Developments - The SOL-X open-label extension trial is expected to begin in Q2 2026, allowing subjects from SOL-1 and SOL-R to enroll for additional safety follow-up [3][21] - The company raised approximately $475 million from an equity offering in September 2025, with net proceeds supporting operations into 2028 [4]

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3] - The CEO, Michael A. Metzger, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026 [1] - The company has notable products in its pipeline, including Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr), both of which are FDA-approved [3] Company Overview - Syndax Pharmaceuticals is dedicated to advancing cancer care through its innovative therapies [3] - The company is conducting several clinical trials to maximize the potential of its product pipeline [3] - Revuforj is a menin inhibitor, while Niktimvo™ is a monoclonal antibody targeting the CSF-1 receptor [3]

Core Insights - Exicure, Inc. announced positive results from a Phase 2 clinical study of burixafor, a selective CXCR4 inhibitor, demonstrating rapid lymphocyte mobilization and potential therapeutic applications beyond transplantation [1][2] Study Results - The Phase 2 study involved 12 participants with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin disease undergoing autologous stem cell transplantation, with 92% achieving the primary endpoint of collecting ≥5.0 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Notably, 6 participants achieved the target in a single session, with median times to neutrophil and platelet engraftment recorded at 12 and 22 days, respectively [3] Mobilization Profile - Burixafor demonstrated peak mobilization of CD34+ cells within one hour of administration, significantly faster than existing CXCR4 inhibitors, which peak at 10-14 hours [4] - This rapid mobilization allows for same-day leukapheresis, potentially simplifying treatment logistics and reducing hospital resource utilization [4] Clinical Implications - The combination of burixafor and G-CSF resulted in substantial increases in circulating lymphocyte counts, with increases of up to 11-fold observed in multiple myeloma patients [5] - The study highlights burixafor's potential applicability in gene therapy and CAR-T cell therapies, which require efficient peripheral blood cell collection [5] Future Development - Exicure is advancing burixafor's clinical development, having completed an additional Phase 2 study combining burixafor with G-CSF and propranolol, with positive topline data presented at recent hematology meetings [6] - The company aims to leverage burixafor's capabilities in various hematologic diseases, including plans for a chemosensitization trial in acute myeloid leukemia [8]

Core Viewpoint - Sagimet Biosciences Inc. is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing novel therapeutics for metabolic and fibrotic conditions [1][4]. Company Overview - Sagimet Biosciences is a clinical-stage biopharmaceutical company specializing in FASN inhibitors aimed at addressing dysfunctional metabolic and fibrotic pathways linked to the overproduction of palmitate [3]. - The company's lead product, denifanstat, has successfully met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial for MASH and in a Phase 3 trial for moderate-to-severe acne in partnership with a licensee in China [3]. - Denifanstat is an oral medication taken once daily, and it is currently being tested in combination with resmetirom in a Phase 1 PK clinical trial for cirrhotic patients with F4-stage MASH [3]. - Another product, TVB-3567, is an oral FASN inhibitor under investigation in a Phase 1 first-in-human clinical trial for acne [3]. Upcoming Events - Sagimet will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, with a fireside chat scheduled for 10am ET [4]. - The company will also be featured at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET [4].

Core Viewpoint - Nuvalent, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on targeted therapies for cancer treatment [1]. Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company that develops precisely targeted therapies aimed at overcoming the limitations of existing treatments for clinically proven kinase targets in cancer [3]. - The company utilizes expertise in chemistry and structure-based drug design to create innovative small molecules that can address issues such as resistance, adverse events, and brain metastases, while promoting durable responses [3]. - Nuvalent is advancing a robust pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3].

分组1: Market Overview - The pre-Davos market exhibited overwhelming bullish sentiment, while the post-Davos environment is characterized by renewed volatility, the Sell-America trade, a rallying gold price, and a consistently weak dollar [1] - A critical shift in global discourse from de-globalization to a new world order necessitates immediate re-imagining of supply chains, partnerships, and advancements in domestic AI and automated manufacturing in the US [1] 分组2: Investment Themes - The anticipated volatility should be viewed as a sign of an emergent market rather than a negative one, with a shift from the MAG7 to 'magnificent thematics' including new world order, AI automation, innovation, and longevity [2] - Investors are encouraged to focus on the other 473 companies in the S&P 500 rather than just mega-caps, as every company is now effectively a tech company [2] 分组3: Stock Recommendations - CRISPR Therapeutics (NASDAQ:CRSP) is highlighted as a stock expected to double by 2030, with a maintained Outperform rating and a reduced price target from $86 to $80, indicating an undervalued pipeline [7][8] - Summit Therapeutics Inc. (NASDAQ:SMMT) is also expected to double by 2030, with the FDA accepting its BLA for ivonescimab, targeting a significant unmet need in non-small cell lung cancer [12][14]

As filed with the U.S. Securities and Exchange Commission on February 4, 2026. Registration No. 333-292664 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________________________ Lakewood-Amedex Biotherapeutics Inc. (Exact Name of Registrant as Specified in its Charter) ________________________________________ | Nevada | 2834 | 20-5274304 | | --- | --- | --- | | (State or Other Jurisdi ...

Core Viewpoint - AbbVie Inc. is a leading biopharmaceutical company with strong financial performance in Q4 2025, driven by its immunology portfolio, and is projected to exceed profit expectations for 2026 [1][2][6] Financial Performance - AbbVie reported Q4 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, marking a 10% increase on a reported basis and a 9.5% increase operationally [2] - Adjusted earnings per share rose by 25.5% to $2.71, surpassing the expected $2.65 [2] Revenue Breakdown - The immunology portfolio generated global net revenues of $8.63 billion, reflecting an 18.3% increase, with Skyrizi sales up 32.5% to $5.01 billion and Rinvoq sales rising 29.5% to $2.37 billion [3] - Neuroscience sales climbed to $2.96 billion, a 17.9% increase, with Vraylar contributing $1.02 billion (up 10.5%) and Botox Therapeutics at $991 million (up 13.4%) [4] - The oncology portfolio saw a slight decline, generating $1.66 billion in sales, with Imbruvica's revenues down 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million [4] Future Projections - AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by strong sales of Skyrizi and Rinvoq [5][6] - The current stock price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69, with a market capitalization of approximately $383.47 billion [5]

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit, Megan Dodge v. Mereo BioPharma Group plc, was initiated in the United States District Court for the Southern District of New York for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - Investors are encouraged to participate in the lawsuit before the April 6, 2026 deadline to potentially recover losses [5]. Group 2: Study Results - Mereo announced on December 29, 2025, that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet the primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [3]. - Despite improvements in bone mineral density, the studies did not yield the expected results, leading to significant investor concerns [2][3]. Group 3: Market Reaction - Following the announcement of the study results, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [4].